Skip to main content

Table 1 Characteristics of included HIV+ subjects and controls

From: Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life

 

pHIVy patients (# = 21)

npHIVy patients (# = 19)a

HC (# = 40)

Age (years); median (IQR)

27 (24–29)

27 (24–29)

28 (24–31)

Males; patients (%)

7 (33)

12 (63)

19 (47.5)

CD4/μl; median (IQR)

803 (526–1052)

818 (688–1024)

851 (643–1099)

CD4, %; median (IQR)

33.8 (28.7–38.8)

38.1 (31.9–42)

42.9 (39.7–49.4)

CD8/μl; median (IQR)

850 (713–1131)

728 (631–812)

415 (344–571)

CD8, %; median (IQR)

42.8 (32.7–51)

32.3 (28–40.3)

22.2 (22.0–22.6)

CD4/CD8 ratio; median (IQR)

0.8 (0.6–1.2)

1.2 (0.8–1.4)

2.0 (2.0–2.5)

Years with HIV; median (IQR)

27* (0)

4* (3–5.5)

NA

HIV viral load < 37 copies/ml; patients

20

19

NA

Hepatitis B surface antigen positive; patients (%)

1 (4.76)

1 (5.26)

NA

Hepatitis C virus-antibody positive; patients (%)b

5 (23.81)

1 (5.26)

NA

Cytomegalovirus IgG positive; patients (%)

13 (61.90)

7 (36.84)

NA

Toxoplasma gondii IgG positive; patients (%)

4 (19.04)

2 (10.52)

NA

Treatment prescribed at enrolment:

 PI + 2 NRTI; patients (%)

4 (19)

5 (26)

NA

 NNRTI + 2 NRT; patients (%)

3 (14)

8 (42)

NA

 INI + 2 NRTI; patients (%)

6 (29)

6 (32)

NA

 INI + PI; patients (%)

7 (33)

0

NA

 INI + NNRTI; patients (%)

1 (5)

0

NA

  1. HC healthy controls, IQR interquartile range, NA not applicable, PI protease inhibitor, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non nucleoside reverse transcriptase inhibitor, INI integrase inhibitor, # number
  2. *P < 0.001 (P-value calculation was done by Fisher exact test for categorial variables and unpaired t test for continuous variables)
  3. a 9 patients were heterosexual, 8 homosexual and 2 bisexual. bAll 6 patients were Sustained Virological Responsers (SVR) to previous anti-HCV therapy with Directly Acting Antivirals (DAA)